zigakibart   Click here for help

GtoPdb Ligand ID: 12101

Synonyms: BION-1301 | BION1301 | clone 14_1G.15
Immunopharmacology Ligand
Compound class: Antibody
Comment: Zigakibart is an anti-TNFSF13 (APRIL) monoclonal antibody that has been designed for anti-inflammatory potential. Amino acid sequences for zigakibart's heavy and light chains (obtained from INN documentation) match the sequences for clone 14_1G.15 as claimed in patent US9969808B2 (Aduro Biotech) [1]. Aduro Biotech merged into Chinook Therapeutics in mid-2020, with this new entity holding the humanized IgG4 anti-APRIL mAb BION-1301 in its development portfolio. We predict that zigakibart is the INN for BION-1301. BION-1301 is described as blocking APRIL binding to both the BCMA and TACI receptors, to down-modulate B cell functions.
No information available.
Summary of Clinical Use Click here for help
Evaluation of BION-1301 for efficacy in patients with IgA nephropathy is ongoing.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03340883 Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2 Interventional Chinook Therapeutics, Inc. This study was terminated as no indicators of beneficial effect were detected following completion of the Phase 1 dose-escalation.
NCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) Phase 1/Phase 2 Interventional Chinook Therapeutics, Inc.